■心房颤动(AF)是危重病人普遍存在的问题,房颤有效治疗策略的可用性有限。
■本研究的目的是评估使用阿司匹林或非阿司匹林的危重患者与房颤相关的死亡率。
■本队列研究纳入了重症监护医疗信息集市数据库中的重症房颤患者。该研究比较了28天死亡率的发生率,90天死亡率,服用和不服用阿司匹林的患者的1年死亡率。为了评估阿司匹林和终点之间的关联,进行Kaplan-Meier分析和Cox比例风险回归分析。
■在这项研究中,共纳入13,330例房颤危重患者,其中4421例和8909例患者被分为阿司匹林和非阿司匹林使用者,分别。28天,90天,1年死亡率为17.5%(2,330/13,330),23.9%(3,180/13,330),和32.9%(4,379/13,330),分别。完全校正的Cox比例风险模型的结果表明,在校正混杂因素后,使用阿司匹林与死亡风险呈负相关(28天死亡率,HR0.64,95%CI0.55-0.74;90天死亡率,HR0.65,95%CI0.58-0.74;1年死亡率,HR0.67,95CI0.6~0.74)。子群分析的结果表明,相关性更强,特别是在65岁以下的患者和没有充血性心力衰竭或心肌梗塞病史的患者中。
■在诊断为心房颤动的危重患者中,阿司匹林的使用可能与所有原因的风险调整死亡率降低相关。然而,需要更多的随机对照试验来阐明和确认这种潜在的关联.
UNASSIGNED: Atrial fibrillation (AF) is a prevalent issue among critically ill patients, and the availability of effective treatment strategies for AF is limited.
UNASSIGNED: The objective of this
study was to evaluate the mortality rate associated with AF in critically ill patients who were either
aspirin or non-
aspirin users.
UNASSIGNED: This cohort
study incorporated critically ill patients with AF from the Medical Information Mart for Intensive Care database. The study compared incidences of 28-day mortality, 90-day mortality, and 1-year mortality between patients with and without
aspirin prescriptions. To assess the association between aspirin and the endpoints, Kaplan-Meier analysis and Cox proportional hazards regression analyses were conducted.
UNASSIGNED: In this study, a total of 13,330 critically ill patients with atrial fibrillation (AF) were included, of which 4,421 and 8,909 patients were categorized as
aspirin and non-
aspirin users, respectively. The 28-day, 90-day, and 1-year mortality rates were found to be 17.5% (2,330/13,330), 23.9% (3,180/13,330), and 32.9% (4,379/13,330), respectively. The results of a fully-adjusted Cox proportional hazard model indicated that aspirin use was negatively associated with the risk of death after adjusting for confounding factors (28-day mortality, HR 0.64, 95% CI 0.55-0.74; 90-day mortality, HR 0.65, 95% CI 0.58-0.74; 1-year mortality, HR 0.67, 95%CI 0.6∼0.74). The results of the subgroup analysis indicate a more robust correlation, specifically among patients under the age of 65 and those without a history of congestive heart failure or myocardial infarction.
UNASSIGNED: The utilization of aspirin may exhibit a correlation with a reduction in risk-adjusted mortality from all causes in critically ill patients diagnosed with atrial fibrillation. However, additional randomized controlled trials are necessary to elucidate and confirm this potential association.